This website is intended for US healthcare professionals only. Prescribing Information Important Safety Information

Template Desktop

How to dose CEPROTIN

CEPROTIN dosing schedule for acute episodes/short-term prophylaxis
and long-term prophylaxis1

Initiate treatment with CEPROTIN under the supervision of a physician experienced in replacement therapy with coagulation factors/inhibitors where monitoring of protein C activity is feasible.1

The dose, administration frequency and duration of treatment with CEPROTIN depends on the severity of the protein C deficiency, the patient’s age, the clinical condition of the patient and the patient’s plasma level of protein C. Therefore, adjust the dose regimen according to the pharmacokinetic profile for each individual patient.1

CEPROTIN DOSING SCHEDULE FOR ACUTE EPISODES, SHORT-TERM PROPHYLAXYS AND LONG-TERM PROPHYLAXIS1,a

INITIAL
DOSEb
SUBSEQUENT
3 DOSESb
MAINTENANCE
DOSEb
acute episode /
short-term
prophylaxisc
100 - 200 IU/kg60 - 80 IU/kg
Q 6 hours
45 - 60 IU/kg
Q 6 OR 12 hours
long-term
prophylaxis
NANA45 - 60 IU/kg
Q 12 hours
aDosing is based upon a clinical trial of 15 patients.

bAdjust the dose according to the pharmacokinetic profile for each individual.

cContinue CEPROTIN until desired anticoagulation is achieved.

NA = Not applicable; Q = every

The measurement of protein C activity using a chromogenic assay is recommended for the determination of the patient’s plasma level of protein C before and during treatment with CEPROTIN. The half-life of CEPROTIN may be shortened in certain clinical conditions such as acute thrombosis, purpura fulminans and skin necrosis.1

In the case of an acute thrombotic event, it is recommended that protein C activity measurements be performed immediately before the next injection until the patient is stabilized. After the patient is stabilized, continue monitoring the protein C levels to maintain the trough protein C level above 25%.1

Patients treated during the acute phase of their disease may display much lower increases in protein C activity.
Coagulation parameters should also be checked. However, in clinical trials, data were insufficient to establish correlation between protein C activity levels and coagulation parameters.1

CEPROTIN dose calculation is based on patient weight1

This graph is an example based on possible new patients born weighing 3 kg.

Consult the CEPROTIN Prescribing information before administering to any patient.

*Doses given are examples calculated using the maximum dose from the recommended range and estimated patient weight.

All doses listed in the below table are given in IUs.

CEPROTIN dose calculation is based on patient weight

Initiation of vitamin K antagonists

– In patients starting treatment with oral anticoagulants belonging to the class of vitamin K antagonists, a transient hypercoagulable state may arise before the desired anticoagulant effect becomes apparent. This transient effect may be explained by the fact that protein C, itself a vitamin K-dependent plasma protein, has a shorter half-life than most of the vitamin K-dependent proteins (i.e Factor II, IX and X).1

– In the initial phase of treatment, the activity of protein C is more rapidly suppressed than that of the procoagulant factors. For this reason, if the patient is switched to oral anticoagulants, protein C replacement must be continued until stable anticoagulation is obtained. Although warfarin-induced skin necrosis can occur in any patient. During the initiation of treatment with oral anticoagulant therapy, individuals with severe congenital protein C deficiency are particularly at risk.1

– During the initiation of oral anticoagulant therapy, it is advisable to start with a low dose of the anticoagulant and adjust this incrementally, rather than use a standard loading dose of the anticoagulant.1

AN INCREASE IN PLASMA PROTEIN C LEVELS WAS OBSERVED DURING THE DOSING TRIAL2

  • The measurement of protein C activity using a chromogenic assay is recommended for the determination of the patient’s plasma level of protein C before and during treatment with CEPROTIN1
  • The half-life of CEPROTIN may be shortened in certain clinical conditions such as acute thrombosis, purpura fulminans and skin necrosis1
  • The dose, administration frequency and duration of treatment with CEPROTIN depends on the severity of the protein C deficiency, the patient’s age, the clinical condition of the patient and the patient’s plasma level of protein C1
  • Adjust the dose regimen according to the pharmacokinetic profile for each individual patient1
  • Patients treated during the acute phase of the disease may display a much lower increase in Protein C activity1
  • Coagulation parameters should be checked1
  • In clinical trials, data were insufficient to establish correlation between protein C activity levels and coagulation parameters

Pre- and Post- Infusion Protein C Activity Levels

  • Administration of CEPROTIN normalized plasma protein C activity levels in the trial.2
  • Results from the multi-center, open-label, non-randomized trial in patients with severe congenital protein C deficiency :
    The median pre-first infusion PC activity level was 2.00 IU/dl and the median post-first infusion PC level was 165.0 IU/dl, based on an average infusion dose of 120 IU/kg body weight. Subsequent to first infusion, PC activity levels increased considerably from pre- to post-treatment.2

A total of 89% of post-infusion (peak) PC levels were within 66-300% (10% within 66-130% and 79% within 131-300% of normal), whereas 9% of the levels were >300% of normal.2

*Protein C activity was measured using the amidolytic test system. Protein C amidolytic activity is determined in comparison with a reference preparation calibrated against the 1st International Standard for Protein C in Plasma, code 86/622 (https://www.who.int/bloodproducts/catalogue/Fibr2015.pdf?ua=1).

 

Please refer to the full prescribing information for complete information on Dosage and Administration.1

Prescribing informationHow to reconstitute CEPROTIN


Click arrow for Indication and Important Safety Information

Warnings and Precautions

Hypersensivity: CEPROTIN may contain trace amounts of mouse protein and/or heparin as a result of the manufacturing process. Allergic reactions to mouse protein and/or heparin cannot be ruled out. If symptoms of hypersensitivity/allergic reaction occur, discontinue the injection/infusion. In case of anaphylactic shock, the current medical standards for treatment are to be observed.

References:

  1. CEPROTIN [Protein C Concentrate (Human)] Prescribing information. Lexington, MA: Baxalta US Inc.
  2. Manco-Johnson MJ, et al. Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency. Thromb Haemost. 2016;116:56-68.

Sign up below

The contact information collected in this form will be used for subscribing to our newsletter and updates on educational activities.

Sorry! There are some errors below that need to be fixed.

You have the right to opt out of receiving such electronic communications and/or our newsletter, at any time, by using the opt out link in the communication or by contacting us at privacyoffice@takeda.com or by calling 1-866-888-0660. For more information on how Takeda processes your personal data, please refer to our Privacy Notice

Please include @ in your email address (eg name@test.com)
*Required
Register

THANKS

Thank you for submitting your details.

You are about to leave this website
Please be advised that Takeda has no control over the content or presentation of the site your are to view. Takeda's Privacy Notice does not apply to the website you are about to visit.
Continue Cancel